PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
144.91%
Positive net income growth while Medical - Pharmaceuticals median is negative at -0.49%. Peter Lynch would view it as a strong advantage vs. struggling peers.
6.03%
D&A growth of 6.03% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
229.18%
Working capital of 229.18% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
-83.06%
Inventory shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
205.43%
Growth of 205.43% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
147.15%
Under 50% of Medical - Pharmaceuticals median of 95.54% if negative or well above if positive. Jim Chanos would flag potential major accounting illusions or revaluations overshadowing underlying performance.
385.68%
Operating cash flow growth exceeding 1.5x Medical - Pharmaceuticals median of 7.69%. Joel Greenblatt would see a strong operational advantage vs. peers.
-9.17%
CapEx declines yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-150.82%
We reduce “other investing” yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
-27.13%
Reduced investing yoy while Medical - Pharmaceuticals median is -3.18%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
-2.89%
Debt repayment yoy declines while Medical - Pharmaceuticals median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.